Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial (vol 49, pg 62, 2020)

首页> 外文期刊>Pancreas >Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial (vol 49, pg 62, 2020)

【24h】

Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial (vol 49, pg 62, 2020)

机译：脂质体Irinotecan + 5-Fu / LV在转移性胰腺癌中：患者，肿瘤和先前治疗特征的亚组分析在枢轴中的Napoli-1试验中（Vol 49，PG 62,2020）

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Pancreas》 |2020年第3期|共1页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类消化系及腹部疾病;
关键词

相似文献

外文文献
中文文献
专利

1. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial (vol 49, pg 62, 2020) [J] . Pancreas . 2020,第3期

机译：脂质体Irinotecan + 5-Fu / LV在转移性胰腺癌中：患者，肿瘤和先前治疗特征的亚组分析在枢轴中的Napoli-1试验中（Vol 49，PG 62,2020）
2. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open label, phase 3 trial (vol 387, pg 545, 2015) [J] . Wang-Gillam A., Li C-P, Bodoky G. The Lancet . 2016,第10018期

机译：纳米脂素伊替替康与氟尿嘧啶和转移性胰腺癌中的叶酸在基于吉西他滨治疗后（Napoli-1）：全球，随机，开放标签，第3阶段试验（Vol 387，PG 545,2015）
3. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors [J] . Wang-Gillam Andrea, Hubner Richard A., Siveke Jens T., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2019,第期

机译：Napoli-1相3研究脂质体菱丙烷在转移性胰腺癌中的研究：最终整体存活分析和长期幸存者的特征
4. PD-023Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy [O] . L.-T. Chen, J. Siveke, A. Wang-Gillam, -1

机译：PD-023 NAPOLI-1中各亚组之间的安全性：先前在转移性胰腺癌（mPAC）中对nal-IRI（MM-398）±5-氟尿嘧啶和亚叶酸钙（5-FU / LV）与5-FU / LV进行的3期研究吉西他滨治疗
5. Selected subgroup analyses of liposomal irinotecan (nal-IRI) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) in the global NAPOLI-1 phase III trial [O] . T. Macarulla Mercadé, K. Lee, G. Lakatos, 2018

机译：在全球Napoli-1期III试验中，选定脂质体IRINOTECAN（NAL-IRI）的脂质体IRINOTECAN（NAL-IRI）分析

Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 Trial (vol 49, pg 62, 2020)

著录项

相似文献

相关主题

期刊订阅